INTELLIA THERAPEUTICS INC (NTLA) Forecast, Price Target & Analyst Ratings

NASDAQ:NTLA • US45826J1051

Current stock price

14.255 USD
+0.77 (+5.67%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INTELLIA THERAPEUTICS INC (NTLA).

Forecast Snapshot

Consensus Price Target

Price Target
$25.16
+ 76.50% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Apr 30, 2026
Period
Q1 / 2026
EPS Estimate
-$0.94
Revenue Estimate
14.763M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
74.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$25.16
Upside
+ 76.50%
From current price of $14.26 to mean target of $25.16, Based on 30 analyst forecasts
Low
$5.05
Median
$16.32
High
$111.30

Price Target Revisions

1 Month
5.08%
3 Months
13.72%

Price Target Summary

30 Wall Street analysts provided a forecast for the next 12 months for NTLA. The average price target is 25.16 USD. This implies a price increase of 76.5% is expected in the next year compared to the current price of 14.255.
The average price target has been revised upward by 13.72% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

NTLA Current Analyst RatingNTLA Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8 10

Analyst Ratings History

NTLA Historical Analyst RatingsNTLA Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 10 20 30

Analyst Ratings Consensus

ChartMill Buy Consensus
74.00%
NTLA was analyzed by 30 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about NTLA.
In the previous month the buy percentage consensus was at a similar level.
NTLA was analyzed by 30 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-04Jones TradingUpgrade Hold -> Buy
2026-03-03CitizensMaintains Market Outperform -> Market Outperform
2026-03-03Leerink PartnersMaintains Outperform -> Outperform
2026-03-03RBC CapitalMaintains Sector Perform -> Sector Perform
2026-03-03Wells FargoMaintains Equal-Weight -> Equal-Weight
2026-03-03Canaccord GenuityMaintains Buy -> Buy
2026-03-03HC Wainwright & Co.Maintains Buy -> Buy
2026-03-02Chardan CapitalMaintains Buy -> Buy
2026-02-27Chardan CapitalMaintains Buy -> Buy
2026-01-28HC Wainwright & Co.Maintains Buy -> Buy
2025-11-12Wolfe ResearchDowngrade Outperform -> Peer Perform
2025-11-11Jones TradingDowngrade Buy -> Hold
2025-11-11Evercore ISI GroupDowngrade Outperform -> In-Line
2025-11-10Truist SecuritiesReiterate Buy -> Buy
2025-11-10HC Wainwright & Co.Maintains Buy -> Buy
2025-11-07CitizensMaintains Market Outperform -> Market Outperform
2025-11-07Chardan CapitalMaintains Buy -> Buy
2025-11-07RBC CapitalMaintains Sector Perform -> Sector Perform
2025-11-07BarclaysMaintains Overweight -> Overweight
2025-11-07WedbushMaintains Neutral -> Neutral
2025-11-07Wells FargoMaintains Equal-Weight -> Equal-Weight
2025-11-07JP MorganDowngrade Neutral -> Underweight
2025-10-30HC Wainwright & Co.Maintains Buy -> Buy
2025-10-28BernsteinDowngrade Outperform -> Market Perform
2025-10-28JMP SecuritiesMaintains Market Outperform -> Market Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
Apr 30, 2026
Period
Q1 / 2026
EPS Estimate
-$0.94
Revenue Estimate
14.763M
Revenue Q2Q
-11.21%
EPS Q2Q
14.99%
Number of Analysts
21

Next Earnings Revisions

Revenue (1 Month)
0.00%
Revenue (3 Months)
22.26%
EPS (1 Month)
0.00%
EPS (3 Months)
3.33%

Next Earnings Summary

NTLA is expected to report earnings on 4/30/2026. The consensus EPS estimate for the next earnings is -0.94 USD and the consensus revenue estimate is 14.76M USD.
The next earnings revenue estimate has been revised upward by 22.26% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
NTLA revenue by date.NTLA revenue by date.
36.275M
-30.40%		57.877M
59.55%		67.671M
16.92%		64.153M
-5.20%		104.41M
62.75%		192.66M
84.52%		1.596B
728.40%		2.404B
50.63%		981.2M
-59.18%		1.448B
47.57%		1.733B
19.68%
EBITDA
YoY % growth
NTLA ebitda by date.NTLA ebitda by date.
-506.315M
-12.37%		-523.978M
-3.49%		-431.223M
17.70%		-442.456M
-2.60%		-413.935M
6.45%		-400.075M
3.35%		-257.756M
35.57%		67.32M
126.12%		370.26M
450.00%		608.94M
64.46%		808.86M
32.83%
EBIT
YoY % growth
NTLA ebit by date.NTLA ebit by date.
-515.291M
-12.47%		-534.263M
-3.68%		-440.99M
17.46%		-466.393M
-5.76%		-446.224M
4.32%		-382.763M
14.22%		-94.926M
75.20%		253.14M
366.67%		294.19M
16.22%		497.61M
69.15%		598.67M
20.31%
Operating Margin
NTLA operating margin by date.NTLA operating margin by date.
-1,420.51%-923.10%-651.67%-727.00%-427.38%-198.67%-5.95%10.53%29.98%34.37%34.55%
EPS
YoY % growth
NTLA eps by date.NTLA eps by date.
-5.41
12.46%		-5.25
2.96%		-3.83
27.05%		-3.68
3.93%		-3.13
15.05%		-2.63
15.84%		-0.45
82.84%		1.69
475.41%		2.05
21.00%		4.09
99.50%		5.48
33.92%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27 Q1 / 28 Q2 / 28 Q3 / 28 Q4 / 28
EPS
Q2Q % growth		-0.94
14.99%		-0.92
6.33%		-0.93
-1.07%		-0.91
-9.68%		-0.93
0.43%		-0.83
9.93%		-0.73
21.46%		-0.71
21.99%		-0.79
14.66%		-0.69
16.85%		-0.69
5.31%		-0.70
1.61%
Revenue
Q2Q % growth		14.763M
-11.21%		14.308M
0.44%		14.669M
6.44%		18.735M
-18.60%		11.356M
-23.08%		14.824M
3.61%		23.072M
57.28%		27.298M
45.71%		2.796M
-75.38%		3.768M
-74.58%		5.487M
-76.22%		6.674M
-75.55%
EBITDA
Q2Q % growth		-107.691M
8.97%		-110.231M
-4.96%		-112.582M
-8.16%		-112.666M
-26.67%		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-113.452M
6.09%		-116.804M
-6.19%		-120.372M
-7.98%		-120.645M
-22.22%		-121.61M
-7.19%		-119.523M
-2.33%		-111.917M
7.02%		-109.503M
9.24%		N/AN/AN/AN/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

NTLA Yearly Revenue VS EstimatesNTLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
NTLA Yearly EPS VS EstimatesNTLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 -10

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
9.51%
EPS Next 5 Year
19.55%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
48.47%
Revenue Next 5 Year
110.00%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
4.34%
EBIT Next 5 Year
16.49%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

INTELLIA THERAPEUTICS INC / NTLA Forecast FAQ

What is the average price target for INTELLIA THERAPEUTICS INC (NTLA) stock?

30 analysts have analysed NTLA and the average price target is 25.16 USD. This implies a price increase of 76.5% is expected in the next year compared to the current price of 14.255.

When does INTELLIA THERAPEUTICS INC (NTLA) report earnings?

INTELLIA THERAPEUTICS INC (NTLA) will report earnings on 2026-04-30.

What are the consensus estimates for NTLA stock next earnings?

The consensus EPS estimate for the next earnings of INTELLIA THERAPEUTICS INC (NTLA) is -0.94 USD and the consensus revenue estimate is 14.76M USD.

How do analysts rate INTELLIA THERAPEUTICS INC (NTLA)?

The consensus rating for INTELLIA THERAPEUTICS INC (NTLA) is 74 / 100 . This indicates that analysts generally have a positive outlook on the stock.